Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 40 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[ ... | - | - | - | - | 1件: 301 301 💬1. (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine
| ||||||||||
| 2 | 4-Methylpyrazole | 1件: Fomepizole Fomepizole | 1件: Fomepizole
Fomepizole
💬2. 4-Methylpyrazole
| 3件: ADH1A ADH1A,ADH1B, ADH1C 💬 | 9件: Alcoholic liver disease Alcoholic liver disease, Drug metabolism - cytochrome P450, Fatty acid degradation, Glycolysis / Gluconeogenesis, Metabolic pathways, Metabolism of xenobiotics by cytochrome P450, Pyruvate metabolism, Retinol metabolism, Tyrosine metabolism 💬 9件: Alcoholic liver disease, Drug metabolism - cytochrome P450, Fatty acid degradation, Glycolysis / ... | 1件: 301 301 💬2. 4-Methylpyrazole
| ||||||||||
| 3 | ACU-4429 | - | - | - | - | 1件: 301 301 💬3. ACU-4429
| ||||||||||
| 4 | ALK-001 | - | - | - | - | 1件: 301 301 💬4. ALK-001
| ||||||||||
| 5 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬5. ALK-001 (No generic name)
| ||||||||||
| 6 | ARC1905 | - | - | - | - | 1件: 301 301 💬6. ARC1905
| ||||||||||
| 7 | ARC1905 20 MG/ML | - | - | - | - | 1件: 301 301 💬7. ARC1905 20 MG/ML
| ||||||||||
| 8 | Avacincaptad pegol | 1件: Avacincaptad pegol Avacincaptad pegol | - | - | - | 1件: 301 301 💬8. Avacincaptad pegol
| ||||||||||
| 9 | Blood and/or skin biopsy | - | - | - | - | 2件: 90 90, 301 💬
| ||||||||||
| 10 | DHA | - | - | - | - | 8件: 6 6, 46, 48, 49, 94, 113, 299, 301 💬10. DHA |